Interpace Biosciences, Inc. (IDXG) — 10-K Filings
All 10-K filings from Interpace Biosciences, Inc.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Interpace Pivots to Thyroid Diagnostics After Key Test Reimbursement Loss
— Mar 30, 2026 Risk: high
Interpace Biosciences, Inc. (IDXG) is a molecular diagnostic company that experienced a significant business change in 2025 due to the Center for Medicare and M -
INTERPACE BIOSCIENCES, INC. Files 2024 10-K
— Mar 31, 2025 Risk: medium
INTERPACE BIOSCIENCES, INC. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Interpa -
INTERPACE BIOSCIENCES, INC. Files 2023 Annual Report on Form 10-K
— Apr 1, 2024 Risk: low
INTERPACE BIOSCIENCES, INC. (IDXG) filed a Annual Report (10-K) with the SEC on April 1, 2024. Filed its annual report on Form 10-K for the fiscal year ended De
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX